Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients.
Dora ČerinaVišnja MatkovićKristina KatićIngrid Belac LovasićRobert ŠeparovićIvana CanjkoBlanka JakšićBranka Petrić-MišeŽarko BajićMarijo BobanEduard VrdoljakPublished in: Journal of oncology (2021)
In a real-world setting, TCB as a first-line treatment of metastatic cervical cancer was associated with longer PFS, better objective disease control rate, and acceptable toxicity profile in comparison to chemotherapy alone. These results may indicate its utility and potential applicability in other parts of the developing world.